Clinical Trial Update: Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure [Phase 2]

View source ↗

Summary

Phase 2 trial comparing daratumumab, bortezomib, and dexamethasone versus cyclophosphamide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Failure
• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Myeloma Multiple | Phase 2 | Status: NOT_YET_RECRUITING